Neogen Chemicals Limited (Neogen) (NSE: NEOGEN, BSE: 542665) is a Thane, Maharashtra-based company in the Custom Synthesis and Specialty CDMO industry. With a market capitalisation of ₹8,322 Cr, it ranks #652 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 13 in Custom Synthesis and Specialty CDMO. At ₹2,775.00 (as of 16 Nov 2026), the share price is 3.5% below its 52-week high of ₹2,875.00 and 183.2% above its 52-week low of ₹979.80. The share price is up 93.4% over one year and up 31.3% over three months.
| Current Price | ₹2,775.00 |
|---|---|
| Market Cap | ₹8,322 Cr |
| NSE Symbol | NEOGEN |
| BSE Code | 542665 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Custom Synthesis and Specialty CDMO |
| P/E Ratio | 259.2 |
| Return on Equity | 3.58% |
| Return on Assets | 2.95% |
| 52-Week Range | ₹979.80 – ₹2,875.00 |
| 1-Year Price Change | +93.4% |
| 3-Month Price Change | +31.3% |
| Beta (1Y) | 0.61 |
| Dividend Yield | 0.04% |
| Headquarters | Thane, Maharashtra |
| Website | www.neogenchem.com |
| Revenue | ₹296 Cr |
|---|---|
| Net Profit | ₹8 Cr |
| Net Margin | 2.8% |
| EPS (Basic) | ₹2.96 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Neogen Chemicals Limited (Neogen) reported revenue of ₹296 Cr in Q2 FY27, up 41.8% from ₹209 Cr in Q2 FY26 and up 18.2% from ₹250 Cr in Q1 FY27. It posted a net profit of ₹8 Cr for the quarter, against a net profit of ₹3 Cr in Q2 FY26 (up 144.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹187 Cr (Q1 FY26) to ₹296 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹296 Cr | ₹8 Cr | 2.8% |
| Q1 FY27 | ₹250 Cr | ₹17 Cr | 6.8% |
| Q4 FY26 | ₹247 Cr | ₹11 Cr | 4.6% |
| Q3 FY26 | ₹220 Cr | ₹4 Cr | 1.7% |
| Q2 FY26 | ₹209 Cr | ₹3 Cr | 1.6% |
| Q1 FY26 | ₹187 Cr | ₹10 Cr | 5.5% |
| Q4 FY25 | ₹203 Cr | ₹2 Cr | 1.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 53.01% of Neogen Chemicals Limited (Neogen)'s shares as of Sept 2026, against 51.23% in Dec 2025 (+1.78 percentage points). Delivery averaged 40.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Neogen Chemicals Limited engages in the manufacture and sale of specialty chemicals in India. It offers organo bromine compounds, such as alkyl bromide compounds, dibromoalkane compounds, bromo chloro alkanes, bromine derivatives of organoacids, bromoacid ester compounds, aromatic bromine derivatives, cyclic bromine derivatives, and speciality bromo fluro derivatives; speciality chloro compounds comprising unsaturated bromine derivatives, bromo hydroxy derivatives, and other compounds; and organo lithium compounds, including n-butyl lithium, lithium hexamethyldisilazide, lithium tetrahydride borate, lithium diisopropylamide, lithium tri-(t-butoxy) aluminium hydride, hexyl lithium, methyl lithium, and phenyl lithium. The company also provides inorganic chemicals comprising inorganic bromine compounds and lithium salts; grignard reagents; advance intermediates; and chemistries, such as alkylation, amination, oxidation, dehalogenation, silylation, anhydrous HF and HBr reactions, suzuki co
1. Manufacturing of Speciality Chemicals-This segment manufacturers of bromine and lithium based specialty chemicals. It offers organic chemicals, such as alkyl bromide compounds, dibromo alkane compounds, and bromo chloro alkanes; specialty chemical compounds; grignard reagents; advance intermediates; inorganic bromine compounds; and lithium salts. The company also provides custom synthesis and contract manufacturing services.
1. Manufacturing of Speciality Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Anupam Rasayan India Ltd | ₹13,570 Cr | 79.6 | 5.76% | ₹806 Cr | +20.1% |
| Neogen Chemicals Limited (Neogen) | ₹8,322 Cr | 259.2 | 3.58% | ₹296 Cr | +93.4% |
| Prasol Chemicals Limited | ₹4,681 Cr | 58.1 | — | ₹413 Cr | — |
| Laxmi Organic Industries Ltd | ₹4,574 Cr | 57.2 | 4.08% | ₹1,083 Cr | -18.9% |
| Tatva Chintan Pharma Chem Ltd | ₹3,871 Cr | 92.5 | 5.53% | ₹217 Cr | +12.2% |
| Paushak Ltd. | ₹1,487 Cr | 38.1 | 8.22% | ₹89 Cr | — |
| Sunshield Chemicals Ltd. | ₹833 Cr | 25.2 | 17.02% | — | +12.6% |
| Chemcon Speciality Chemicals Limited | ₹733 Cr | 31.8 | 4.80% | ₹65 Cr | -12.8% |
| Resonance Specialties Ltd. | ₹327 Cr | 31.5 | 15.15% | — | +203.4% |
Listed by market capitalisation. Ratios are shown for context only.
Neogen Chemicals Limited (Neogen) is trading at ₹2,775.00, with a market capitalisation of ₹8,322 Cr.
Neogen Chemicals Limited (Neogen) operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Custom Synthesis and Specialty CDMO).
Neogen Chemicals Limited (Neogen) has a P/E of 259.2 and a return on equity of 3.58%.
Neogen Chemicals Limited (Neogen) is listed on the NSE under the symbol NEOGEN and on the BSE under the scrip code 542665.
Neogen Chemicals Limited (Neogen)'s share price is up 93.4% over one year and up 31.3% over three months. Its 52-week range is ₹979.80 to ₹2,875.00.
In Q2 FY27, Neogen Chemicals Limited (Neogen) reported revenue of ₹296 Cr and net profit of ₹8 Cr, with basic EPS of ₹2.96 (consolidated, parsed from the company's exchange filing).
Neogen Chemicals Limited (Neogen) reported revenue of ₹296 Cr in Q2 FY27, up 41.8% from ₹209 Cr in Q2 FY26 and up 18.2% from ₹250 Cr in Q1 FY27.
Promoters held 53.01% of Neogen Chemicals Limited (Neogen)'s shares as of Sept 2026, against 51.23% in Dec 2025 (+1.78 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.